by David Rubin | Oct 16, 2024 | In the Press
Meet Dr. David T Rubin – EPISODE...
by David Rubin | Sep 23, 2024 | In the Press
A University of Chicago Medicine patient became the first person with ulcerative colitis in the world to receive the drug guselkumab (Tremfya) since its Sept. 11 approval by the FDA for treating moderate to severe ulcerative colitis. Tremfya has been used for many...
by David Rubin | Apr 23, 2024 | In the Press, Presentations
Dr. Rubin provides an in-depth look at the treatment of ulcerative colitis, from recent advances in therapeutic agents to setting patient expectations, positioning treatments, and monitoring for disease remission or progression. Click here for the full talk from the...
by David Rubin | Jan 19, 2024 | In the Press
Intestinal ultrasound has become a useful tool in assessing disease progression and pathophysiology of inflammatory bowel disease (IBD). It’s an approach to visualizing the intestines using a transabdominal ultrasound probe to provide real-time information. But could...
by David Rubin | Oct 25, 2023 | In the Press
At this year’s ACG (American College of Gastroenterology) Conference in Vancouver, British Columbia, Canada, Dr. Noa Krugliak Cleveland gave an oral presentation on her award-winning abstract “Monitoring IBD by Intestinal Ultrasound Decreases Time to...
by David Rubin | Oct 19, 2023 | In the Press
Take a listen to the third episode of a four-part series wherein Professor Rubin guest-hosts the Gastroenterology Learning Network’s IBD Drive Time and discusses the ethics of clinical trials in IBD, as well as challenges to recruitment, alongside Professor...
